The supplied quote records a previous close of $2.18 and an open of $2.13. Shares traded between $2.104 and $2.175, with volume of 616,843 against an average of 1,771,090.
The listed bid was $1.91 for 200 shares; the ask was $3.28 for 200 shares. The snapshot gives Fate Therapeutics a market capitalization of $255.218 million and a one-year target estimate of $5.74. That target is an estimate, not a reported outcome. The same snapshot lists a trailing net loss of $126 million.
In the second quarter of 2026, Fate Therapeutics reported $2.08 million in revenue, a net loss of $30.159 million and negative operating cash flow of $23.434 million.
A pipeline at different evidence stages
Fate develops ready-to-use cellular immunotherapies derived from induced pluripotent stem cells, or iPSCs. Its engineered CAR T- and NK-cell candidates target cancer and autoimmune disorders. The company describes its approach as using synthetic controls to direct cell functions.
Among its CAR-targeted NK- and T-cell candidates, FT836 is preclinical and aimed at multiple tumor types. FT522 targets B-cell lymphoma and autoimmunity. Fate’s CAR T-cell programs include FT819 for lupus. FT839 is being developed for autoimmune diseases, while FT825 targets solid tumors.
On October 12, 2026, Fate appointed Jamie Harrell senior vice-president of market development and commercial operations. Harrell will guide commercial strategy for FT819 and FT839 while both remain in clinical development. The company said FT819 had entered the potentially registrational Phase 2 RECLAIM-LN study in refractory lupus nephritis. FT839 was being studied in a Phase 1/2 trial across autoimmune diseases, including rheumatoid arthritis, according to this executive and pipeline update.
Fate also has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. The deal covers development and commercialization of off-the-shelf, iPSC-derived CAR T-cell candidates for solid tumors. It establishes a development relationship; the supplied snapshot reports no clinical result from the agreement. GenoMethods previously outlined the company’s programmes in this pipeline overview.
In September 2025, a court dismissed investor claims against Fate tied to its terminated collaboration with Janssen. Law360 also reported a separate refusal to award about $7 million in legal fees in a patent dispute.
Losses and cash frame the investment picture
Fate reported $6.49 million in trailing revenue. Diluted EPS was negative $1.05, and the listed profit margin was 0.00%. Return on assets was negative 26.22%; return on equity was negative 60.75%.
The supplied balance-sheet snapshot lists $153.77 million in cash and a total debt-to-equity ratio of 49.32%. Levered free cash flow was negative $48.66 million. Separately, Ad-Hoc-News reported $32.429 million in cash and equivalents as of June 30, 2026. The supplied snapshot gives no comparable reporting date, so the two cash figures should not be treated as measurements from the same date. The quarterly report is summarized in these quarterly financial figures.
The estimated next earnings date is November 12, 2026. Fate scheduled appearances at the Jefferies Global Healthcare Conference beginning November 16 and the Piper Sandler Annual Healthcare Conference beginning December 1, 2026. The company identified both as upcoming public opportunities for investors to hear about its pipeline, not as confirmed clinical readouts.
The pipeline snapshot does not show that any candidate has succeeded clinically or commercially. It presents a high-risk development-stage profile, with multiple therapeutic bets alongside substantial losses and negative free cash flow. The $5.74 target estimate remains separate from demonstrated clinical value.
